Cellectar Biosciences
CLRB
8 hedge funds and large institutions have $1.72M invested in Cellectar Biosciences in 2015 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and closing their positions.
14% more funds holding
Funds holding: 7 → 8 (+1)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
66% less capital invested
Capital invested by funds: $5.13M → $1.72M (-$3.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$679K |
| 2 |
VKH
Virtu KCG Holdings
New York
|
+$42.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$1.57M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$9K |
| 3 |
BCM
Brookstone Capital Management
Wheaton,
Illinois
|
-$4K |
| 4 |
SSB
Sandy Spring Bank
Olney,
Maryland
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $633K | +$679K | +16 | +123% |
|
|
AIC
2
AWM Investment Company
New York
| $595K | -$1.57M | -37 | -51% |
|
|
CAM
3
Cormorant Asset Management
Boston,
Massachusetts
| $390K | – | – | – |
|
4
Geode Capital Management
Boston,
Massachusetts
| $33K | – | – | – |
|
|
BA
5
Bard Associates
Chicago,
Illinois
| $29K | – | – | – |
|
6
Goldman Sachs
New York
| $16K | – | – | – |
|
|
VKH
7
Virtu KCG Holdings
New York
| $13K | +$42.5K | +1 | New |
|
|
WAM
8
Wealthspire Advisors (Maryland)
Potomac,
Maryland
| $8K | – | – | – |
|
9
Morgan Stanley
New York
| $2K | – | – | – |
|
10
Bank of America
Charlotte,
North Carolina
| $1K | – | – | – |
|
11
Bank of Montreal
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
|
BCM
12
Brookstone Capital Management
Wheaton,
Illinois
| – | -$4K | – | – |
|
|
SSB
13
Sandy Spring Bank
Olney,
Maryland
| – | -$1K | – | – |
|
|
14
UBS Group
Zurich,
Switzerland
| – | -$9K | – | – |
|
CLRB Hedge Fund Activity: Q4 2015 in Review
8 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Cellectar Biosciences (CLRB) for Q4 2015, worth a combined $1.72M — down 66% from $5.13M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CLRB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Sabby Management, adding an estimated $679K. The largest seller was AWM Investment Company, cutting an estimated $1.57M.
- 8 institutional investors held Cellectar Biosciences (CLRB) as of Q4 2015, up from 7 in Q3 2015.
- Funds reported $1.72M of Cellectar Biosciences stock for Q4 2015, down 66% quarter-over-quarter.
- 1 fund opened new Cellectar Biosciences positions in Q4 2015 and 0 closed out, a net change of +1 holder.
- The largest Cellectar Biosciences buyer in Q4 2015 was Sabby Management, an estimated $679K added.
- The largest Cellectar Biosciences seller in Q4 2015 was AWM Investment Company, an estimated $1.57M sold.
Based on aggregated 13F filings for Q4 2015.